Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QuantRx Announces Multi Year Technology License Agreement With Church & Dwight
QuantRx expects that the product will be launched by Church & Dwight under its First Response brand and will be available at the retail level in the second
QuantRx expects that the product will be launched by Church & Dwight under its First Response brand and will be available at the retail level in the second
Highlights Total operating expenses increased $2,225 or less than 1% vs. the prior year’s comparable quarter. Operating loss for the quarter was $61,060 vs. $62,913 for the prior
The lead clinical development program for dirucotide is for secondary progressive multiple sclerosis (MS) where it is being evaluated in two ongoing Phase III trials in the US,
The establishment of a US-based R&D and commercial operation represents attainment of one of the Helsinn Group’s corporate strategic goals. Helsinn has appointed Franco Vecchi, who is already
According to the company, the E coli/P aeruginosa PNA FISH is the first-ever test for identifying E coli and P aeruginosa directly from positive blood cultures and the
The Phase II study is a single-blind, placebo-controlled, dose-escalation trial expected to enroll a total of 130 patients with anemia of chronic kidney disease (CKD) who are not
Kapidex (30mg and 60mg) is the first proton pump inhibitor (PPI) with a dual delayed release formulation designed to provide two separate releases of medication. The approval was
Kahr Medical’s drug development pipeline is built around the ‘trans signal converter proteins (TSCP)’ technology, a novel drug technology invented by Mark Tykocinski and licensed from the University
The Office of the Chief Scientist (OCS) has approved this second-year grant to support Modigene’s hGH-CTP program for the period September 2008 through August 2009. The grant will
The acquired assets include all of Cyberkinetics’s rights and regulatory filings for the Andara Oscillating Field Stimulator (OFS) technology for treatment of acute spinal cord injury, an investigational